Metabolic features’ effect on FibroScan-AST (FAST) score in Egyptian patients with metabolic dysfunction-associated steatotic liver disease (MASLD) Amal Mohammed Dwidar, Ayat Ismail Ferra, Amany Mohammed Dwidar, Eslam Saber Esmail, Rania Mamdouh Elkafoury Egyptian Liver Journal.2026;[Epub] CrossRef
A landscape of liver cirrhosis and transplantation in Mexico: Changing leading causes and transplant as response Icela Palma-Lara, María Guadalupe Ortiz-López, José Bonilla-Delgado, Juanita Pérez-Escobar, Ricardo Godínez-Aguilar, Claudia Luévano-Contreras, Ana María Espinosa-García, Javier Pérez-Durán, Patricia García Alonso-Themann, Manuel Nolasco-Quiroga, Javier F Annals of Hepatology.2025; 30(1): 101562. CrossRef
Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fib Won Sohn Clinical and Molecular Hepatology.2025; 31(1): 277. CrossRef
Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease Klaudia Nowak, Krzysztof Łupina, Anna Romac, Aleksandra Kalisz, Łucja Ilkiewicz, Jakub Janczura Annals of Pharmacotherapy.2025; 59(10): 928. CrossRef
Hepatoprotective activity of mulberry extract in NAFLD mice for regulating lipid metabolism and inflammation identified via AMPK/PPAR-γ/NF-κB axis Li-juan Zhang, Shun-ying Li, Shao-li Fan, Aobulikasimu nuerbiye, Jiu-yang Zhao, Bahetiyaer Keremu, Lu Yang, Ke Zhang, Hang-yu Wang, Jin-hui Wang Journal of Ethnopharmacology.2025; 351: 120108. CrossRef
Non-alcoholic fatty liver disease versus cirrhosis in rotator cuff repair: Differential risks and complication profiles in a matched national cohort Catherine Hand, Jared Sasaki, Camden Bohn, Francis Hand, Kyleen Jan, Daniel Shinn, Brian Forsythe Journal of Orthopaedics.2025; 69: 244. CrossRef
A New Korean Nomenclature for Steatotic Liver Disease
The Korean Journal of Medicine.2024; 99(4): 189. CrossRef
A New Korean Nomenclature for Steatotic Liver Disease
The Korean Journal of Gastroenterology.2024; 84(1): 1. CrossRef
A New Korean Nomenclature for Steatotic Liver Disease
Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis” Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen Clinical and Molecular Hepatology.2023; 29(1): 176. CrossRef
SARS-CoV-2 and chronic hepatitis B: Focusing on the possible consequences of co-infection Shahrzad Shoraka, Seyed Reza Mohebbi, Seyed Masoud Hosseini, Amir Ghaemi, Mohammad Reza Zali Journal of Clinical Virology Plus.2023; 3(4): 100167. CrossRef
Post-COVID-19 cholangiopathy: Systematic review Mazen Abdalla Rasheed, Vinícius Remus Ballotin, Lucas Goldmann Bigarella, Jonathan Soldera World Journal of Methodology.2023; 13(4): 296. CrossRef
Hepatitis B in Africa: Progress toward World Health Organization 2030 targets, persistent disparities, and COVID-19 setbacks Kui Wang, Ruchen Zhou Clinical and Molecular Hepatology.2026; 32(2): e211. CrossRef
Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis” Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen Clinical and Molecular Hepatology.2023; 29(1): 176. CrossRef
SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes Luke Baldelli, Thomas Marjot, Eleanor Barnes, A. Sidney Barritt, Gwilym J. Webb, Andrew M. Moon Gut and Liver.2023; 17(1): 12. CrossRef
Analysis of Antibody Responses After COVID-19 Vaccination in Liver Transplant Recipients: A Single-Center Study Young Ju Oh, Jongman Kim, Eun-Suk Kang, Jinsoo Rhu, Gyu-Seong Choi, Jae-Won Joh Journal of Korean Medical Science.2023;[Epub] CrossRef
Acute Budd‐Chiari syndrome with thrombotic thrombocytopenia after BNT162b2 mRNA vaccination Pil S. Sung, Jung S. Oh, Joon‐Il Choi Liver International.2022; 42(6): 1447. CrossRef
Forms of cholangitis to be considered after SARS-CoV-2 infection Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim Clinical and Molecular Hepatology.2022; 28(4): 929. CrossRef
Autoimmune liver disease represented as primary biliary cholangitis after SARS-CoV-2 infection: A need for population-based cohort study Soon Kyu Lee, Jung Hyun Kwon, Nara Yoon, Soon Woo Nam, Pil Soo Sung Clinical and Molecular Hepatology.2022; 28(4): 926. CrossRef
Impact of Coronavirus Disease 2019 on Unresectable Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab Yun Beom Sang, Chaeryoung Lee, Seul-Gi Kim, Boyoung Lee, Beodeul Kang, Chan Kim, Hong Jae Chon Journal of Clinical Medicine.2024; 13(5): 1335. CrossRef
SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes Luke Baldelli, Thomas Marjot, Eleanor Barnes, A. Sidney Barritt, Gwilym J. Webb, Andrew M. Moon Gut and Liver.2023; 17(1): 12. CrossRef
Autoimmune liver disease represented as primary biliary cholangitis after SARS-CoV-2 infection: A need for population-based cohort study Soon Kyu Lee, Jung Hyun Kwon, Nara Yoon, Soon Woo Nam, Pil Soo Sung Clinical and Molecular Hepatology.2022; 28(4): 926. CrossRef
Forms of cholangitis to be considered after SARS-CoV-2 infection Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim Clinical and Molecular Hepatology.2022; 28(4): 929. CrossRef
Management of Patients with Chronic Liver Disease: The Era of the COVID-19 Pandemic Yu Rim Lee The Korean Journal of Gastroenterology.2021; 77(4): 156. CrossRef
Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim Clinical and Molecular Hepatology.2021; 27(4): 515. CrossRef
Maintaining standard volumes, efficacy and safety, of fecal microbiota transplantation for C. difficile infection during the COVID-19 pandemic: A prospective cohort study Gianluca Ianiro, Stefano Bibbò, Luca Masucci, Gianluca Quaranta, Serena Porcari, Carlo Romano Settanni, Loris Riccardo Lopetuso, Massimo Fantoni, Maurizio Sanguinetti, Antonio Gasbarrini, Giovanni Cammarota Digestive and Liver Disease.2020; 52(12): 1390. CrossRef
Background/Aims This study aimed to develop and validate a risk prediction model for the development of hepatocellular carcinoma (HCC) in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B (CHB).
Methods We investigated 2,061 Korean treatment-naïve patients with CHB treated with entecavir as an initial therapy. A risk score model for HCC development was developed based on multivariable Cox regression model in a single center (n=990) and was validated using the time-dependent area under the receiver operating characteristic curve (AUROC) in three other centers (n=1,071). The difference of HCC development among risk groups (low, intermediate, and high) categorized by risk score was also investigated.
Results The cumulative incidence rates of HCC at 5 years were 11.2% and 8.9% in the testing and validation cohorts, respectively. HCC-Risk Estimating Score in CHB patients Under Entecavir (HCC-RESCUE) is formulated as (age+15×gender [female=0 / male=1]+23×cirrhosis [absence=0 / presence=1]). The AUROCs at 1 year, 3 years, and 5 years were 0.82, 0.81, and 0.81, respectively, in the validation cohort. A significant difference of HCC development in each risk group was determined by the 5-year HCC risk score in the validation cohort (low risk group, 2.1%; intermediate risk group, 9.3%; high risk group, 41.2%, p<0.001).
Conclusions The study presents a new risk score model with a good ability to predict HCC development and determine high risk patients for HCC development consisting of readily available clinical factors in treatment-naïve CHB patients receiving entecavir.
Citations
Citations to this article as recorded by
Risk Scores for Stratifying Hepatocellular Carcinoma and Optimizing Surveillance Strategies Yu-Ping Chang, Yun-Chu Chen, Chen-Hua Liu Cancers.2026; 18(1): 158. CrossRef
AGA Clinical Practice Update on Risk Stratification and Emerging Surveillance Strategies for Hepatocellular Carcinoma: Expert Review Nicole E. Rich, Augusto Villanueva, Jorge A. Marrero, Fasiha Kanwal Gastroenterology.2026; 170(7): 1606. CrossRef
A systematic review and time-specific meta-analysis of hepatocellular carcinoma risk prediction models Jingru Huang, Wenwen Jiang, Chaoqiang Jiang, Weisen Zhang, Feng Zhu, Jing Pan, Tai Hing Lam Oncology and Translational Medicine.2026;[Epub] CrossRef
Behaviour‐Based Predictive Scores of Hepatocellular Carcinoma in People With Chronic Hepatitis B (ANRS CO22 HEPATHER) Clémence Ramier, Camelia Protopopescu, Vincent Di Beo, Lucia Parlati, Fabienne Marcellin, Fabrice Carrat, Tarik Asselah, Marc Bourlière, Patrizia Carrieri Liver International.2025;[Epub] CrossRef
Validation Study of Scores Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Nucleos(t)ide Analogues Jun Inoue, Shinichiro Minami, Kazumichi Abe, Mami Kida, Hiroaki Haga, Chikara Iino, Hiroshi Numao, Hidekatsu Kuroda, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Masazumi Onuki, Satoko Sawahashi, Keishi Ouchi, Kengo Watanabe, Takehiro Akahane, Tomoo Kobay Journal of Viral Hepatitis.2025;[Epub] CrossRef
A Review of Risk Prediction Model for Hepatocellular Carcinoma in Chronic Hepatitis B Jiwon Yang, Mark D. Muthiah, Won-Mook Choi Current Hepatology Reports.2025;[Epub] CrossRef
MR elastography-based prediction of development of hepatocellular carcinoma in patients with chronic hepatitis B with sustained virological response Haimei Chen, Jie Zhu, Jinhui Zhou, Ziying Yin, Jun Chen, Sudhakar K. Venkatesh, Meng Yin, Richard L. Ehman, Jin Wang European Radiology.2025; 35(12): 8032. CrossRef
Current and new strategies for hepatocellular carcinoma surveillance Natchaya Polpichai, Chongkonrat Maneenil, Pojsakorn Danpanichkul, Chitchai Rattananukrom, Ashok Choudhury, Yu Jun Wong, Pimsiri Sripongpun, Suthat Liangpunsakul, Apichat Kaewdech Gastroenterology Report.2025;[Epub] CrossRef
Score-based prediction model for female hepatocellular carcinoma surveillance in asymptotic HBsAg carriers: a multicenter cohort study in China Mengdi Cao, Maomao Cao, Changfa Xia, Fan Yang, Xinxin Yan, Siyi He, Shaoli Zhang, Yi Teng, Qianru Li, Nuopei Tan, Jiachen Wang, Chunfeng Qu, Wanqing Chen Journal of the National Cancer Center.2025; 5(5): 493. CrossRef
Dynamic changes in liver stiffness measurement by 2D shear-wave elastography predict hepatocellular carcinoma in patients with chronic hepatitis B and well-controlled viremia: a retrospective study Nana Wang, Yuankai Wu, Mingyue Xiao, Yusheng Jie, Jinfen Wang, Manli Wu, Jiaxin Chen, Liuping Sha, Zhongzhen Su, Yutian Chong, Lili Wu BMC Gastroenterology.2025;[Epub] CrossRef
Liver Stiffness Measurements After Oral Antivirals Effectively Predict the Risk of HCC in Patients With Chronic Hepatitis C Yu Rim Lee, Hyun Young Woo, Young Oh. Kweon, Won Young Tak, Se Young Jang, Jung Gil Park, Min Kyu Kang, Jeong Eun Song, Byoung Kuk Jang, Changhyeong Lee, Byung Seok Kim, Jae Seok Hwang, Woo Jin Chung, Jeong Heo, Nae‐Yun Heo, Seung Ha Park, Jun Sik Yoon, J Journal of Gastroenterology and Hepatology.2025; 40(10): 2568. CrossRef
Early screening for liver cancer must be performed Zi-Han Liu, Wen-Jun Wang, Shuang-Suo Dang World Journal of Hepatology.2025;[Epub] CrossRef
A prediction nomogram for hepatitis B virus-associated hepatocellular carcinoma Yijin Zhang, Gang Wan, Hongjie Li, Lili Gao, Nan Liu, Ping Gao, Yaping Liu, Xuesong Gao, Xuefei Duan Scandinavian Journal of Gastroenterology.2024; 59(1): 70. CrossRef
A Liver Stiffness–Based Etiology-Independent Machine Learning Algorithm to Predict Hepatocellular Carcinoma Huapeng Lin, Guanlin Li, Adèle Delamarre, Sang Hoon Ahn, Xinrong Zhang, Beom Kyung Kim, Lilian Yan Liang, Hye Won Lee, Grace Lai-Hung Wong, Pong-Chi Yuen, Henry Lik-Yuen Chan, Stephen Lam Chan, Vincent Wai-Sun Wong, Victor de Lédinghen, Seung Up Kim, Terr Clinical Gastroenterology and Hepatology.2024; 22(3): 602. CrossRef
Applicability of Risk Scores to an Indian Cohort of Hepatitis B-Related Hepatocellular Carcinoma Patients Gautam Ray Journal of Clinical and Experimental Hepatology.2024; 14(4): 101370. CrossRef
Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Sang Hoon Ahn, Won Kim, Jin Mo Yang, Jae Young Jang, Yong Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Joo Hyun Sohn, Jin Woo Lee, Sung Jae Park, Sun Young Yim, Jin Kyung Park, Soon Cancers.2024; 16(5): 887. CrossRef
Prognostic significance of dynamic changes in liver stiffness measurement in patients with chronic hepatitis B and compensated advanced chronic liver disease Hongsheng Yu, Yinan Huang, Mingkai Li, Hao Jiang, Bilan Yang, Xiaoli Xi, Abdukyamu Smayi, Bin Wu, Yidong Yang Journal of Gastroenterology and Hepatology.2024; 39(10): 2169. CrossRef
Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma Lung-Yi Mak Journal of Liver Cancer.2024; 24(2): 145. CrossRef
Risk predictive model for the development of hepatocellular carcinoma before initiating long‐term antiviral therapy in patients with chronic hepatitis B virus infection Junjie Chen, Tienan Feng, Qi Xu, Xiaoqi Yu, Yue Han, Demin Yu, Qiming Gong, Yuan Xue, Xinxin Zhang Journal of Medical Virology.2024;[Epub] CrossRef
Risk stratification and early detection biomarkers for precision HCC screening Yi‐Te Lee, Naoto Fujiwara, Ju Dong Yang, Yujin Hoshida Hepatology.2023; 78(1): 319. CrossRef
Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment Jun Li, Xiao-Qin Dong, Li-Hua Cao, Zhan-Qing Zhang, Wei-Feng Zhao, Qing-Hua Shang, Da-Zhi Zhang, An-Lin Ma, Qing Xie, Hong-Lian Gui, Guo Zhang, Ying-Xia Liu, Jia Shang, Shi-Bin Xie, Yi-Qi Liu, Chi Zhang, Gui-Qiang Wang, Hong Zhao Frontiers in Cellular and Infection Microbiology.2023;[Epub] CrossRef
HCC prediction models in chronic hepatitis B patients receiving entecavir or tenofovir: a systematic review and meta-analysis Xiaolan Xu, Lushun Jiang, Yifan Zeng, Liya Pan, Zhuoqi Lou, Bing Ruan Virology Journal.2023;[Epub] CrossRef
Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy Beom Kyung Kim, Sang Hoon Ahn Journal of the Formosan Medical Association.2023; 122(12): 1238. CrossRef
Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection Chih-Lin Lin, Jia-Horng Kao Clinical and Molecular Hepatology.2023; 29(3): 605. CrossRef
A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B Hye Won Lee, Hwiyoung Kim, Taeyun Park, Soo Young Park, Young Eun Chon, Yeon Seok Seo, Jae Seung Lee, Jun Yong park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim Liver International.2023; 43(8): 1813. CrossRef
Improving prediction of hepatocellular carcinoma in chronic hepatitis B by machine learning: Productive relationship of medicine with computer science Terry C. F. Yip, Cihan Yurdaydin Liver International.2023; 43(8): 1626. CrossRef
Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States Hyun-seok Kim, Xian Yu, Jennifer Kramer, Aaron P. Thrift, Pete Richardson, Yao-Chun Hsu, Avegail Flores, Hashem B. El-Serag, Fasiha Kanwal Journal of Hepatology.2022; 76(2): 294. CrossRef
An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B Hwi Young Kim, Pietro Lampertico, Joon Yeul Nam, Hyung-Chul Lee, Seung Up Kim, Dong Hyun Sinn, Yeon Seok Seo, Han Ah Lee, Soo Young Park, Young-Suk Lim, Eun Sun Jang, Eileen L. Yoon, Hyoung Su Kim, Sung Eun Kim, Sang Bong Ahn, Jae-Jun Shim, Soung Won Jeon Journal of Hepatology.2022; 76(2): 311. CrossRef
An MRI-Based Radiomic Model for Individualized Prediction of Hepatocellular Carcinoma in Patients With Hepatitis B Virus-Related Cirrhosis Yichen Wei, Jie Gong, Xin He, Bo Liu, Tiejun Liu, Shuohui Yang, Zhipeng Zhou, Lingyan Liang, Songhua Zhan, Ziqiang Xia, Gaoxiong Duan, Bin Lin, Qiuli Han, Shasha Li, Wei Qin, Perry J. Pickhardt, Demao Deng Frontiers in Oncology.2022;[Epub] CrossRef
Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis Ze-Hong Huang, Gui-Yang Lu, Ling-Xian Qiu, Guo-Hua Zhong, Yue Huang, Xing-Mei Yao, Xiao-Hui Liu, Shou-Jie Huang, Ting Wu, Quan Yuan, Ying-Bin Wang, Ying-Ying Su, Jun Zhang, Ning-Shao Xia BMC Cancer.2022;[Epub] CrossRef
Hepatitis B Virus-Associated Hepatocellular Carcinoma Giacomo Emanuele Maria Rizzo, Giuseppe Cabibbo, Antonio Craxì Viruses.2022; 14(5): 986. CrossRef
External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B Thierry Poynard, Jean Marc Lacombe, Olivier Deckmyn, Valentina Peta, Sepideh Akhavan, Fabien Zoulim, Victor de Ledinghen, Didier Samuel, Philippe Mathurin, Vlad Ratziu, Dominique Thabut, Chantal Housset, Hélène Fontaine, Stanislas Pol, Fabrice Carrat Gastro Hep Advances.2022; 1(4): 604. CrossRef
The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection Jung Hwan Yu, Soon Gu Cho, Young-Joo Jin, Jin-Woo Lee Clinical and Molecular Hepatology.2022; 28(3): 351. CrossRef
Effect of entecavir and tenofovir disoproxil fumarate on hepatocellular carcinoma in subjects with chronic hepatitis B: a meta-analysis Sara M. Tony, Mohamed E. A. Shaaban, Ahmed I. M. Mohamed, Mohamed E. A. Abdelrahim Beni-Suef University Journal of Basic and Applied Sciences.2022;[Epub] CrossRef
A Mac-2 Binding Protein Glycosylation Isomer-Based Risk Model Predicts Hepatocellular Carcinoma in HBV-Related Cirrhotic Patients on Antiviral Therapy Chien-Hung Chen, Tsung-Hui Hu, Jing-Houng Wang, Hsueh-Chou Lai, Chao-Hung Hung, Sheng-Nan Lu, Cheng-Yuan Peng Cancers.2022; 14(20): 5063. CrossRef
Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim Diagnostics.2022; 13(1): 3. CrossRef
Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir Jin Won Chang, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yeon Seok Seo, Han Ah Lee, Mi Na Kim, Yu Rim Lee, Seong Gyu Hwang, Kyu Sung Rim, Soon Ho Um, Won Young Tak, Young Oh Kweon, Soo Young Park, Seung Up Kim Journal of Viral Hepatitis.2021; 28(1): 95. CrossRef
Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control Pierre Nahon, Erwan Vo Quang, Nathalie Ganne-Carrié Journal of Clinical Medicine.2021; 10(2): 353. CrossRef
Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update James Lok, Kosh Agarwal Viruses.2021; 13(7): 1333. CrossRef
Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it? Coskun Ozer Demirtas, Maurizia Rossana Brunetto World Journal of Gastroenterology.2021; 27(33): 5536. CrossRef
Prediction models for development of hepatocellular carcinoma in chronic hepatitis B patients Jiang Guo, Xue-Song Gao World Journal of Clinical Cases.2021; 9(14): 3238. CrossRef
Validation of the HCC‐RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy Fatih Güzelbulut, Pınar Gökçen, Güray Can, Gupse Adalı, Ayça Gökçen Değirmenci Saltürk, Özgür Bahadır, Kamil Özdil, Hamdi Levent Doğanay Journal of Viral Hepatitis.2021; 28(5): 826. CrossRef
Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B George V. Papatheodoridis, George N. Dalekos, Ramazan Idilman, Vana Sypsa, Florian Van Boemmel, Maria Buti, Jose Luis Calleja, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Margarita Papatheodoridi, Nikolaos Gatselis, Rhea Veelken, Marta Lopez-G JHEP Reports.2021; 3(3): 100290. CrossRef
Screening for Hepatocellular Carcinoma in Patients with Hepatitis B Yashasavi Sachar, Mayur Brahmania, Renumathy Dhanasekaran, Stephen E. Congly Viruses.2021; 13(7): 1318. CrossRef
Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future Perspective Yao-Chun Hsu, Cheng-Hao Tseng, Yen-Tsung Huang, Hwai-I Yang Seminars in Liver Disease.2021; 41(03): 285. CrossRef
Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy Seung Up Kim, Yeon Seok Seo, Han Ah Lee, Mi Na Kim, Eun Hwa Kim, Ha Yan Kim, Yu Rim Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seong Gyu Hwang, Kyu Sung Rim, Soon Ho Um, Won Young Tak, Young Oh Kweon, Beom Kyung Kim, Soo Clinical Gastroenterology and Hepatology.2020; 18(3): 693. CrossRef
Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B Thodoris Voulgaris, Margarita Papatheodoridi, Pietro Lampertico, George V. Papatheodoridis Liver International.2020; 40(3): 484. CrossRef
Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis Xinhui Wang, Xiaoli Liu, Zhibo Dang, Lihua Yu, Yuyong Jiang, Xianbo Wang, Zhiyun Yan Gut and Liver.2020; 14(2): 232. CrossRef
Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review Cheng‐Hao Tseng, Chao‐Ming Tseng, Jia‐Ling Wu, Yao‐Chun Hsu, Hashem B. El-Serag Journal of Gastroenterology and Hepatology.2020; 35(10): 1684. CrossRef
Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review Mohamed A Abd El Aziz, Rodolfo Sacco, Antonio Facciorusso Antiviral Chemistry and Chemotherapy.2020; 28: 204020662092133. CrossRef
Obstacles and opportunities in the prevention and treatment of HBV-related hepatocellular carcinoma Yong Liao Genes & Diseases.2020; 7(3): 291. CrossRef
Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy Joon Yeul Nam, Dong Hyun Sinn, Junho Bae, Eun Sun Jang, Jin-Wook Kim, Sook-Hyang Jeong JHEP Reports.2020; 2(6): 100175. CrossRef
Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine George V. Papatheodoridis, Thodoris Voulgaris, Margarita Papatheodoridi, W. Ray Kim Hepatology.2020; 72(6): 2197. CrossRef
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine Naoto Fujiwara, Scott L. Friedman, Nicolas Goossens, Yujin Hoshida Journal of Hepatology.2018; 68(3): 526. CrossRef
Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B Yao-Chun Hsu, Terry Cheuk-Fung Yip, Hsiu J. Ho, Vincent Wai-Sun Wong, Yen-Tsung Huang, Hashem B. El-Serag, Teng-Yu Lee, Ming-Shiang Wu, Jaw-Town Lin, Grace Lai-Hung Wong, Chun-Ying Wu Journal of Hepatology.2018; 69(2): 278. CrossRef
Effect of Metabolic Syndrome on the Clinical Outcomes of Chronic Hepatitis B Patients with Nucleos(t)ide Analogues Treatment Nam Hee Kim, Yong Kyun Cho, Byung Ik Kim, Hong Joo Kim Digestive Diseases and Sciences.2018; 63(10): 2792. CrossRef
Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy Ji Hyun Kim, Young Don Kim, Minjong Lee, Baek Gyu Jun, Tae Suk Kim, Ki Tae Suk, Seong Hee Kang, Moon Young Kim, Gab Jin Cheon, Dong Joon Kim, Soon Koo Baik, Dae Hee Choi Journal of Hepatology.2018; 69(5): 1066. CrossRef
Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy Byeong G. Song, Dong H. Sinn, Sangah Chi, Kyunga Kim, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon S. Choi, Joon H. Lee, Kwang C. Koh, Seung W. Paik European Journal of Gastroenterology & Hepatology.2018; 30(12): 1447. CrossRef
Development of a nomogram for screening of hepatitis B virus-associated hepatocellular carcinoma Jung Wha Chung, Eun Sun Jang, Jaihwan Kim, Sook-Hyang Jeong, Nayoung Kim, Dong Ho Lee, Kyung Ho Lee, Jin-Wook Kim Oncotarget.2017; 8(63): 106499. CrossRef
Background/Aims Radiofrequency ablation (RFA) is one of the most frequently applied curative treatments in patients with a single small hepatocellular carcinoma (HCC). However, the clinical significance of and risk factors for early massive recurrence after RFA—a dreadful event limiting further curative treatment—have not been fully evaluated.
Methods In total, 438 patients with a single HCC of size ≤3 cm who underwent percutaneous RFA as an initial treatment between 2006 and 2009 were included. Baseline patient characteristics, overall survival, predictive factors, and recurrence after RFA were evaluated. In addition, the incidence, impact on survival, and predictive factors of early massive recurrence, and initial recurrence beyond the Milan criteria within 2 years were also investigated.
Results During the median follow-up of 68.4 months, recurrent HCC was confirmed in 302 (68.9%) patients, with early massive recurrence in 27 patients (6.2%). The 1-, 3-, and 5-year overall survival rates were 95.4%, 84.7%, and 81.8%, respectively, in patients with no recurrence, 99.6%, 86.4%, and 70.1% in patients with recurrence within the Milan criteria or late recurrence, and 92.6%, 46.5%, and 0.05% in patients with early massive recurrence. Multivariable analysis identified older age, Child-Pugh score B or C, and early massive recurrence as predictive of poor overall survival. A tumor size of ≥2 cm and tumor location adjacent to the colon were independent risk factors predictive of early massive recurrence.
Conclusions Early massive recurrence is independently predictive of poor overall survival after RFA in patients with a single small HCC. Tumors sized ≥2 cm and located adjacent to the colon appear to be independent risk factors for early massive recurrence.
Citations
Citations to this article as recorded by
BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update Maria Reig, Marco Sanduzzi-Zamparelli, Alejandro Forner, Jordi Rimola, Joana Ferrer-Fàbrega, Marta Burrel, Ángeles Garcia-Criado, Alba Díaz, Neus Llarch, Gemma Iserte, Meritxell Mollà, Robin K. Kelley, Peter R. Galle, Vincenzo Mazzaferro, Riad Salem, Brun Journal of Hepatology.2026; 84(3): 631. CrossRef
Long-Term Analysis of Recurrence Beyond Milan Criteria Following Ablation of Solitary Early-Stage Hepatocellular Carcinoma ≤3 cm in Potentially Transplantable Patients: A Over 10-Year Survival Study Shuanggang Chen, Han Qi, Hongtong Tan, Fei Cao, Lin Xie, Tao Huang, Ying Wu, Chunyong Wen, Yujia Wang, Lujun Shen, Weijun Fan Journal of Hepatocellular Carcinoma.2025; Volume 12: 205. CrossRef
Investigation into the efficiency and prognostic elements of CT-guided ¹²⁵I particle implantation for liver cancer Yuxiao Xia, Quanyu Zhou, Xue Jiang, Wenling Tu, Qian Liu, Liangshan Li, Yuhong Shi Cancer Imaging.2025;[Epub] CrossRef
Recurrence patterns and survival outcomes after irreversible electroporation for hepatocellular carcinoma: a 6-year multicenter experience Min Xu, Shanyu Yin, Qiyu Zhao, Guo Tian, Jinhua Pan, Gang Dong, Wu Zhang, Tuerganaili Aji, Jiansong Ji, Xinhua Chen, Danxia Xu, Tian’an Jiang European Radiology.2025; 36(3): 2305. CrossRef
Prognostic model for predicting recurrence in hepatocellular carcinoma patients with high systemic immune-inflammation index based on machine learning in a multicenter study Ningning Lu, Shugui Sheng, Yiqi Xiong, Chuanren Zhao, Wenying Qiao, Xiaoyan Ding, Jinglong Chen, Yonghong Zhang Frontiers in Immunology.2024;[Epub] CrossRef
Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients—A Multiparametric Prediction Sergio Muñoz-Martínez, Victor Sapena, Ángeles García-Criado, Anna Darnell, Alejandro Forner, Ernest Belmonte, Marco Sanduzzi-Zamparelli, Jordi Rimola, Alexandre Soler, Neus Llarch, Gemma Iserte, Ezequiel Mauro, Carmen Ayuso, Jose Rios, Jordi Bruix, Ramon Cancers.2023; 15(13): 3269. CrossRef
Decoding Immune Signature to Detect the Risk for Early-Stage HCC Recurrence Aswathy R. Devan, Bhagyalakshmi Nair, Manu Kanjoormana Aryan, Vijayastelar B. Liju, Joel Joy Koshy, Bijo Mathew, Arun Valsan, Hoon Kim, Lekshmi R. Nath Cancers.2023; 15(10): 2729. CrossRef
Predictive Factors of Treatment Outcomes After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in the Hepatocaval Confluence: A Propensity Score Matching Analysis Yanzhao Zhou, Kun Yuan, Yi Yang, Xiao Shan, Zemin Ji, Dezheng Zhou, Jingzhong Ouyang, Zhengzheng Wang, Qi Zhang, Jinxue Zhou, Qiang Li Academic Radiology.2023; 30: S92. CrossRef
Risk factors for recurrence beyond Milan criteria after radiofrequency ablation in transplantable small hepatocellular carcinoma Weike Chu, Ping Li, Xue Wu, Peng Zhang, Hui Zhou, Bin Niu Revista Española de Enfermedades Digestivas.2022;[Epub] CrossRef
Surgery versus radiofrequency ablation in patients with Child- Pugh class-A/single small (≤3 cm) hepatocellular carcinoma Jungnam Lee, Young-Joo Jin, Seung Kak Shin, Jung Hyun Kwon, Sang Gyune Kim, Young Ju Suh, Yujin Jeong, Jung Hwan Yu, Jin-Woo Lee, Oh Sang Kwon, Soon Woo Nahm, Young Seok Kim Clinical and Molecular Hepatology.2022; 28(2): 207. CrossRef
Percutaneous thermal ablation combined with transcatheter arterial chemoembolization for hepatitis C virus-related hepatocellular carcinoma: Efficacy and survival Yu Sun, Honghai Zhang, Jiang Long, Yonghong Zhang, Jiasheng Zheng, Chunwang Yuan Frontiers in Oncology.2022;[Epub] CrossRef
Non‐transplantable recurrence after percutaneous thermal ablation of ≤3‐cm HCC: Predictors and implications for treatment allocation Cecilia Gozzo, Margaux Hermida, Astrid Herrero, Fabrizio Panaro, Christophe Cassinotto, Azhar Meerun Mohamad, Eric Assenat, Chloé Guillot, Carole Allimant, Valentina Schembri, Antonio Basile, Sébastien Dharancy, José Ursic‐Bedoya, Boris Guiu Hepatology Communications.2022; 6(10): 2975. CrossRef
Integrated Analysis Revealing the Role Of TET3-Mediated MUC13 Promoter Hypomethylation in Hepatocellular Carcinogenesis Ruijiao Kong, Hui Zhang, Yin Jia, Qiuhong Man, Shanrong Liu Epigenomics.2022; 14(24): 1579. CrossRef
Risk factors of secondary infection/recurrence after ablation for liver cancers: A systemic review and meta-analysis Gang Yin, Nengwei Zhang, AMin BuHe, Wei Yan, Tianxiong Li, Jirun Peng Journal of Cancer Research and Therapeutics.2022; 18(5): 1352. CrossRef
Risk Factors, Patterns, and Long-Term Survival of Recurrence After Radiofrequency Ablation With or Without Transarterial Chemoembolization for Hepatocellular Carcinoma Jingjun Huang, Wensou Huang, Yongjian Guo, Mingyue Cai, Jingwen Zhou, Liteng Lin, Kangshun Zhu Frontiers in Oncology.2021;[Epub] CrossRef
Four types of tumor progression after microwave ablation of single hepatocellular carcinoma of ≤5 cm: incidence, risk factors and clinical significance Zhimei Huang, Zhixing Guo, Jiayan Ni, Mengxuan Zuo, Tianqi Zhang, Rong Ma, Chao An, Jinhua Huang International Journal of Hyperthermia.2021; 38(1): 1164. CrossRef
Radiofrequency ablation with four electrodes as a building block for matrix radiofrequency ablation: Ex vivo liver experiments and finite element method modelling. Influence of electric and activation mode on coagulation size and geometry Stefaan Mulier, Ricardo Possebon, Yansheng Jiang, Jacques Jamart, Chong Wang, Yi Miao, Tongfu Yu, Kuirong Jiang, Yuanbo Feng, Guy Marchal, Luc Michel, Yicheng Ni Surgical Oncology.2020; 33: 145. CrossRef
Long-term outcome of intraoperative radiofrequency ablation for hepatocellular carcinoma and its efficacy as a primary treatment Jongduk Kwon, Kwang-Sik Chun, In-Sang Song, Seok-Hwan Kim, Sunjong Han Annals of Hepato-Biliary-Pancreatic Surgery.2020; 24(1): 24. CrossRef
Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik Clinical and Molecular Hepatology.2020; 26(4): 516. CrossRef
Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation Hsin-Yeh Chen, Sheng-Nan Lu, Chao-Hung Hung, Jing-Houng Wang, Chien-Hung Chen, Yi-Hao Yen, Yuan-Hung Kuo, Kwong-Ming Kee, Tatsuo Kanda PLOS ONE.2020; 15(11): e0242113. CrossRef
Feasibility, efficacy, and safety of percutaneous MR‐guided ablation of small (≤12 mm) hepatic malignancies Jakob Weiss, Rüdiger Hoffmann, Hansjoerg Rempp, David‐Emanuel Keβler, Philippe L. Pereira, Konstantin Nikolaou, Stephan Clasen Journal of Magnetic Resonance Imaging.2019; 49(2): 374. CrossRef
Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization Min Young Baek, Jeong-Ju Yoo, Soung Won Jeong, Jae Young Jang, Yong Kwon Kim, Shin Ok Jeong, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim, Yong Jae Kim, Su Yeon Park The Korean Journal of Internal Medicine.2019; 34(6): 1223. CrossRef
Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients Adam Doyle, Andre Gorgen, Hala Muaddi, Aloysious D. Aravinthan, Assaf Issachar, Oleg Mironov, Wei Zhang, John Kachura, Robert Beecroft, Sean P. Cleary, Anand Ghanekar, Paul D. Greig, Ian D. McGilvray, Markus Selzner, Mark S. Cattral, David R. Grant, Lesli Journal of Hepatology.2019; 70(5): 866. CrossRef
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma Matteo Canale, Paola Ulivi, Francesco Giuseppe Foschi, Emanuela Scarpi, Serena De Matteis, Gabriele Donati, Giorgio Ercolani, Mario Scartozzi, Luca Faloppi, Alessandro Passardi, Emiliano Tamburini, Martina Valgiusti, Giorgia Marisi, Giovanni Luca Frassine Critical Reviews in Oncology/Hematology.2018; 129: 44. CrossRef
A new scoring model predicting macroscopic vascular invasion of early-intermediate hepatocellular carcinoma Yao Liu, Le Sun, Fangyuan Gao, Xue Yang, Yuxin Li, Qun Zhang, Bingbing Zhu, Shuaishuai Niu, Yunyi Huang, Ying Hu, Ying Feng, Yuyong Jiang, Xianbo Wang Medicine.2018; 97(49): e13536. CrossRef
Traitement ablatif pour cancer du rein : modalités d’évaluation pré-, per-, post-intervention et prise en charge adaptée J. Garnon, T. Tricard, R.L. Cazzato, X. Cathelineau, A. Gangi, H. Lang Progrès en Urologie.2017; 27(15): 971. CrossRef
Editorial: rifaximin in cirrhosis—is this what we've been waiting for? Authors’ reply S. H. Kang, Y. B. Lee, J.‐H. Lee Alimentary Pharmacology & Therapeutics.2017; 46(10): 1017. CrossRef
First
Prev
